I HAVE RECENTLY READ - Vaginal progesterone and risk for preterm birth (March 2016)

Vaginal progesterone and risk for preterm birth (March 2016)

 Progesterone (intramuscular or vaginal) is administered to pregnant women with a history of preterm birth or a short cervix in the current pregnancy to reduce the risk of preterm birth. However, a recent large trial did not observe a benefit for vaginal progesterone. In the OPPTIMUM trial, over 1200 women at high risk for preterm birth by various criteria were randomly assigned to receive either vaginal progesterone or a placebo daily, beginning at 22 to 24 weeks of gestation and ending at 34 weeks [7]. Progesterone supplementation did not reduce any of the primary study outcomes: fetal death or birth before 34 weeks; neonatal death, brain injury, or bronchopulmonary dysplasia; cognitive score at two years of age.
 

We continue to suggest hydroxyprogesterone caproate injections for women with a previous preterm birth because this drug was effective in previous trials and not evaluated by this trial. We continue to suggest vaginal progesterone for women with a short cervix since this population was not the focus of this trial. An updated meta-analysis addressing vaginal progesterone supplementation for women with a short cervix that includes data from this new trial would be helpful. (See "Progesterone supplementation to reduce the risk of spontaneous preterm birth", section on 'OPPTIMUM (progesterone capsules vaginally)'.)

     

 
     

Click here to view other articles in this section